Saturday, November 2, 2024
Canada’s Politics and Government News Source Since 1989
Saturday, November 2, 2024 | Latest Paper

Gary Kobinger

To be competitive in today's vaccine development, we need to be capable of producing mRNA, DNA-based, vectored-based, and protein-based vaccines and promote novel vaccination strategies, write Sen. Rosa Galvez, Gary Kobinger, and Jacques Corbeil. Photograph courtesy of Pexels
To be competitive in today's vaccine development, we need to be capable of producing mRNA, DNA-based, vectored-based, and protein-based vaccines and promote novel vaccination strategies, write Sen. Rosa Galvez, Gary Kobinger, and Jacques Corbeil. Photograph courtesy of Pexels
To be competitive in today's vaccine development, we need to be capable of producing mRNA, DNA-based, vectored-based, and protein-based vaccines and promote novel vaccination strategies, write Sen. Rosa Galvez, Gary Kobinger, and Jacques Corbeil. Photograph courtesy of Pexels
To be competitive in today's vaccine development, we need to be capable of producing mRNA, DNA-based, vectored-based, and protein-based vaccines and promote novel vaccination strategies, write Sen. Rosa Galvez, Gary Kobinger, and Jacques Corbeil. Photograph courtesy of Pexels